Related Experiment Video

Updated: Oct 20, 2025

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
09:16

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis

Published on: June 18, 2020

7.0K

Development and validation of a discrimination model between primary PLA2R-negative membranous nephropathy and

Feng Wu1, Yiding Zhang1, Wen Cui1

  • 1Department of Nephrology, The First Affiliated Hospital, Zhengzhou University, No. 1, East Jianshe Road, Zhengzhou, 450052, Henan, People's Republic of China.

Scientific Reports
|September 11, 2021
PubMed

Insights

A new model using age, albumin, urea, HDL, C3, and RBC count can help differentiate between membranous nephropathy (MN) and minimal change disease (MCD) in patients without a biopsy. This noninvasive tool aids in diagnosis when M-type phospholipase A2 receptor (PLA2R) testing is inconclusive.

Area of Science:

  • Nephrology
  • Immunology

Background:

  • Membranous nephropathy (MN) and minimal change disease (MCD) are leading causes of nephrotic syndrome (NS) with overlapping clinical presentations.
  • Distinguishing between MN and MCD is crucial as they require different therapeutic approaches and have varied prognoses.
  • While M-type phospholipase A2 receptor (PLA2R) is a marker for MN, its sensitivity is limited (approx. 70%), necessitating alternative diagnostic methods for PLA2R-negative cases.

Purpose of the Study:

  • To develop and validate a noninvasive diagnostic model to differentiate between PLA2R-negative idiopathic MN and MCD.
  • To identify key clinical and laboratory parameters that can effectively distinguish these two conditions without the need for renal biopsy.

Main Methods:

  • A cohort of 949 patients with pathologically confirmed idiopathic MN (805) or MCD (144) was analyzed.
  • A logistic regression model was developed using data from 200 PLA2R-negative MN and 144 MCD patients, incorporating basic information and laboratory results.
  • The model's performance was evaluated using area under the curve (AUC) in training and testing groups, and further validated on the entire patient cohort.

Main Results:

  • A novel discrimination model incorporating age, albumin, urea, high-density lipoprotein (HDL) levels, C3 levels, and red blood cell (RBC) count was established.
  • The model demonstrated strong discriminatory power, with an AUC of 0.904 in the training group and 0.886 in the test group.
  • The model also showed good discrimination when applied to the entire cohort of 949 patients, highlighting its robustness.

Conclusions:

  • The developed model offers a promising noninvasive tool for differentiating PLA2R-negative MN from MCD.
  • This approach can aid clinicians in making timely and accurate diagnoses, potentially avoiding invasive procedures like kidney biopsies.
  • The model's inclusion of readily available clinical and laboratory parameters makes it a practical diagnostic aid in nephrotic syndrome management.

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

587
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.1K

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
160
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
38
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
31
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
220